Virgil A. Woods

MDL-001: an Oral, Direct-Acting Broad-Spectrum Antiviral for Influenza-Like Illness (ILI) and Chronic Hepatitis In Vivo

This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.

AmesNet: A Task-Conditioned Deep Learning Model with Enhanced Sensitivity and Generalization in Ames Mutagenicity Prediction

AmesNet improves mutagenicity prediction by enhancing sensitivity without sacrificing balanced accuracy in novel chemical spaces.

Structures of human PTP1B variants reveal allosteric sites to target for weight loss therapy

The paper identifies functional PTP1B variants in thin individuals and uses structural biology to reveal allosteric sites for obesity drug development.

GALILEO Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next Generation Broad-Spectrum Antiviral Compounds at High Hit Rates

This study uses GALILEO and ChemPrint to generate novel antiviral compounds targeting the conserved Thumb-1 site, achieving 100% hit rate in vitro against HCV and Coronavirus 229E.

Allosteric regulation of the tyrosine phosphatase PTP1B by a protein-protein interaction

This paper shows that Grb2 binding to PTP1B allosterically enhances its catalytic activity through structural changes, revealing a new regulatory mechanism for PTP1B in cell signaling.

The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral Development

The paper identifies the RdRp Thumb-1 pocket as a conserved target for broad-spectrum antivirals, validated through structural and biochemical analyses of multiple viruses.

ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery

ChemPrint improves drug discovery by enhancing hit rates and chemical novelty through a novel AI framework, achieving higher performance on challenging targets.